ALS is the most common form of adult-onset motor neuron disease and kills over 1,200 people a year in the UK.
The researchers developed a new model to study neurodegeneration in the common fruit fly (Drosophila melanogaster). In contrast to other methods used to study neurodegeneration such as looking at changes in eye morphology or studying larval stages, the researchers focused their attention on studying the neurons in a fruit fly’s leg. Using the leg allows the detailed study of a single motor neuron, the nerve cell involved in passing signals from the brain to a muscle. Compared to studying larval stages, the model also permits genuine ageing studies as changes in neurons can be observed in flies of different ages. The adult fruit fly can live for over two months in the lab. Furthermore, the fruit fly also provides the benefits of rapid development (ten days from egg to adult), allowing high-throughput genetic screens.
As described online in Current Biology, the researchers used the new model to study the role of a protein central to the development of ALS called TDP-43. Specifically overexpressing TDP-43 in fly legs caused neurodegeneration. Exposing these flies to a mutagen and looking for offspring showing reduced neurodegeneration allowed the researchers to identify three genes implicated in mediating the effects of TDP-43. One, shaggy/GSK3, was already know to be associated with the neurodegeneration process but two of them, hat-trickand xmas-2, were new discoveries.
Dr Jemeen Sreedharan, Senior Research Fellow in the signalling research programme at the Babraham Institute and lead author on the paper said: “We’re extremely excited about our new approach to using the power of Drosophila genetics. Never before has anyone been able to study adult neurodegeneration in an invertebrate system with such ease. By modelling the earliest stages of ALS (synaptic and axon degeneration) we have identified three intriguing genetic suppressors of degeneration in the fly and are now validating these results in mammalian neuronal cultures. We hope that by using the fly we can accelerate progress towards eventually developing therapies for ALS and other neurodegenerative diseases.”
Funding support for this research was provided by the Medical Research Council, a Motor Neurone Disease Association Lady Edith Wolfson Fellowship and the Max Rosenfeld Fund. The Babraham Institute receives strategic funding (a total of £28.8M in 2013-14) from the Biotechnology and Biological Sciences Research Council (BBSRC).
BBSRC Media Office
+44 1793 414694